Q92837 (FRAT1_HUMAN) Homo sapiens (Human)
Proto-oncogene FRAT1 UniProtKBInterProSTRINGInteractive Modelling
279 aa; Sequence (Fasta)
No models could be built to increase the coverage beyond existing experimental structures for this target sequence.
Sequence Alignments
Experimental structures
| Description | Oligo-state | Ligands | Structure | Range |
|---|---|---|---|---|
| Glycogen synthase kinase-3 beta (GSK3) complex with FRATtide peptide |
Heteromer P49841; | 2×SO4; | 1gng | |
| Assess | ||||
| Identification of 2-(4-pyridyl)thienopyridinones as GSK-3beta inhibitors |
Heteromer P49841; | 6×SO4; 3×GOL; 2×ZRL; | 3zrl | |
| Assess | ||||
| GSK3beta complex with N-(6-(3,4-dihydroxyphenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)acetamide |
Heteromer P49841; | 3×SO4; 1×B4K; | 5oy4 | |
| Assess | ||||
| Identification of 2-(4-pyridyl)thienopyridinones as GSK-3beta inhibitors |
Heteromer P49841; | 2×SO4; 2×GOL; 1×ZRK; | 3zrk | |
| Assess | ||||
| Identification of 2-(4-pyridyl)thienopyridinones as GSK-3beta inhibitors |
Heteromer P49841; | 6×SO4; 2×GOL; 2×ZRM; | 3zrm | |
| Assess | ||||
| 5-aryl-4-carboxamide-1,3-oxazoles: potent and selective GSK-3 inhibitors |
Heteromer P49841; | 3×SO4; 3×GOL; 1×SJJ; | 4afj | |
| Assess | ||||